A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration
Status:
Active, not recruiting
Trial end date:
2020-04-05
Target enrollment:
Participant gender:
Summary
This study is designed for single-center, open-label, dose escalation phase I trial to
evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients
with wet AMD.